Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Respir Res ; 19(1): 90, 2018 05 10.
Article in English | MEDLINE | ID: mdl-29747640

ABSTRACT

BACKGROUND: Fibrocytes are implicated in Idiopathic Pulmonary Fibrosis (IPF) pathogenesis and increased proportions in the circulation are associated with poor prognosis. Upon tissue injury, fibrocytes migrate to the affected organ. In IPF patients, circulating fibrocytes are increased especially during exacerbations, however fibrocytes in the lungs have not been examined. Therefore, we sought to evaluate if fibrocytes can be detected in IPF lungs and we compare percentages and phenotypic characteristics of lung fibrocytes with circulating fibrocytes in IPF. METHODS: First we optimized flow cytometric detection circulating fibrocytes using a unique combination of intra- and extra-cellular markers to establish a solid gating strategy. Next we analyzed lung fibrocytes in single cell suspensions of explanted IPF and control lungs and compared characteristics and numbers with circulating fibrocytes of IPF. RESULTS: Using a gating strategy for both circulating and lung fibrocytes, which excludes potentially contaminating cell populations (e.g. neutrophils and different leukocyte subsets), we show that patients with IPF have increased proportions of fibrocytes, not only in the circulation, but also in explanted end-stage IPF lungs. These lung fibrocytes have increased surface expression of HLA-DR, increased intracellular collagen-1 expression, and also altered forward and side scatter characteristics compared with their circulating counterparts. CONCLUSIONS: These findings demonstrate that lung fibrocytes in IPF patients can be quantified and characterized by flow cytometry. Lung fibrocytes have different characteristics than circulating fibrocytes and represent an intermediate cell population between circulating fibrocytes and lung fibroblast. Therefore, more insight in their phenotype might lead to specific therapeutic targeting in fibrotic lung diseases.


Subject(s)
Fibroblasts/pathology , Idiopathic Pulmonary Fibrosis/pathology , Leukocytes, Mononuclear/pathology , Lung/pathology , Cells, Cultured , Female , Fibroblasts/metabolism , Flow Cytometry/methods , Humans , Idiopathic Pulmonary Fibrosis/metabolism , Leukocytes, Mononuclear/metabolism , Lung/metabolism , Male
2.
Transpl Infect Dis ; 15(6): E243-9, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24298985

ABSTRACT

Treatment of cytomegalovirus (CMV) disease in transplant patients is challenging and, with antiviral resistance to first-line drugs, it remains uncertain which treatment algorithm to follow. Some data suggest that leflunomide, a pyrimidine synthesis inhibitor, can be used to treat resistant CMV infections. We report a 57-year-old CMV immunoglobulin-G (IgG)-seronegative woman, who received a bilateral lung transplant (LuTx) from a CMV IgG-positive donor with CMV primary disease. The CMV strain was genotypically resistant to ganciclovir, foscarnet, and cidofovir. After starting leflunomide as add-on therapy to a multidrug anti-CMV regimen, viral load declined substantially in 2 months without adverse events. This experience is discussed against the background of existing literature on the use of leflunomide as an anti-CMV agent in LuTx recipients.


Subject(s)
Antiviral Agents/therapeutic use , Cytomegalovirus Infections/drug therapy , Isoxazoles/therapeutic use , Lung Transplantation/adverse effects , Cytomegalovirus/drug effects , Cytomegalovirus Infections/transmission , Drug Resistance, Viral , Drug Therapy, Combination , Female , Foscarnet/therapeutic use , Ganciclovir/therapeutic use , Humans , Immunoglobulins/therapeutic use , Leflunomide , Middle Aged , Viral Load
3.
Pulm Pharmacol Ther ; 26(6): 672-6, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23380438

ABSTRACT

PRM-151, recombinant human Pentraxin-2 (PTX-2) also referred to as serum amyloid P (SAP), is under development for treatment of fibrosis. A First-in-Human (FIH) trial was performed to assess the safety, tolerability, and pharmacokinetics of single ascending intravenous doses of PRM-151 administered to healthy subjects, using a randomized, blinded, placebo controlled study design. Each cohort included three healthy subjects (PRM-151:placebo; 2:1). SAP levels were assessed using a validated ELISA method, non-discriminating between endogenous and exogenous SAP. At a dose level of 10 mg/kg, at which a physiologic plasma level of SAP was reached, two additional healthy volunteers and three pulmonary fibrosis (PF) patients were enrolled enabling comparison of the pharmacokinetic SAP profile between healthy volunteers and PF patients. In addition, the percentage of fibrocytes (CD45+/Procollagen-1+ cells) in whole blood samples was assessed to demonstrate biological activity of PRM-151 in the target population. PRM-151 administration was generally well tolerated. In two pulmonary fibrosis patients non-specific, transient skin reactions (urticaria and erythema) were observed. PRM-151 administration resulted in a 6-to 13-fold increase in mean baseline plasma SAP levels at dose levels of 5, 10, and 20 mg/kg. The estimated t1/2 of PRM-151 in healthy volunteers was 30 h. Pharmacokinetic profiles were comparable between healthy volunteers and PF patients. PRM-151 administration resulted in a 30-50% decrease in fibrocyte numbers 24 h post-dose. This suggests that administration of PRM-151 may be associated with a reduction of fibrocytes in PF patients, a population for which current pharmacotherapeutic options are limited. The pharmacological action of PRM-151 should be confirmed in future research.


Subject(s)
Homeodomain Proteins/administration & dosage , Pulmonary Fibrosis/drug therapy , Serum Amyloid P-Component/administration & dosage , Adolescent , Adult , Aged , Case-Control Studies , Dose-Response Relationship, Drug , Double-Blind Method , Enzyme-Linked Immunosorbent Assay , Female , Half-Life , Homeodomain Proteins/adverse effects , Homeodomain Proteins/pharmacokinetics , Humans , Male , Middle Aged , Pulmonary Fibrosis/physiopathology , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Recombinant Proteins/pharmacokinetics , Serum Amyloid P-Component/adverse effects , Serum Amyloid P-Component/pharmacokinetics , Young Adult
5.
J Immunol Methods ; 351(1-2): 13-23, 2009 Dec 31.
Article in English | MEDLINE | ID: mdl-19804781

ABSTRACT

BACKGROUND: Dendritic cells (DCs) play a pivotal role in linking the innate and adaptive immune response and have been implicated in a variety of pulmonary diseases. Currently, studies on the role of DCs are limited by difficulties in isolating DCs from the lung. Surgical lung specimens are not readily available and purification of DCs from digested lung tissue is likely to induce phenotypical and functional changes. DCs obtained from the alveolar spaces are thought to represent the local microenvironment and can be obtained using minimally invasive techniques. We developed a novel method of isolating DCs from bronchoalveolar lavage (BAL) fluid. METHODS: After removal of macrophages, the remaining BAL cells were stained with a lineage mix (CD3-, CD14-, CD16-, CD19-, CD56-FITC), CD11c and HLA-DR and sorted with a FACS ARIA. DAPI was used as a dead-live marker. mDCs were low autofluorescent, lineage mix negative, CD11c+ and HLA-DR+ cells. pDCs were CD11c(-) but CD123+. Morphological assessment of sorted mDCs and pDCs was performed. Sorted mDCs were tested in a mixed leukocyte reaction (MLR) with naive CD4+ T cells and evaluated for T cell differentiation and cytokine production. With confocal microscopy DC-T cell interaction was assessed. RESULTS: Using our sorting strategy, mDCs and pDCs, with a high purity upon FACS analysis of the sorted fraction, were obtained. These cells showed the morphological characteristics of DCs. Most importantly, mDCs were able to induce T cell proliferation and differentiation in a MLR, and interact with T cells as assessed by confocal microscopy. These results indicate the presence of functional DCs. Freezing and thawing of the BAL cells did not affect phenotype or T cell stimulatory capacity of the isolated DCs. CONCLUSION: Using a novel sorting strategy, functional mDCs can be isolated from BAL fluid, enabling a detailed study in pulmonary disease.


Subject(s)
Bronchoalveolar Lavage Fluid/cytology , CD4-Positive T-Lymphocytes/metabolism , Cell Separation/methods , Dendritic Cells/cytology , Dendritic Cells/metabolism , Antigens, CD/immunology , Antigens, CD/metabolism , Bronchoalveolar Lavage Fluid/immunology , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/pathology , Cell Differentiation , Cytokines/metabolism , Dendritic Cells/immunology , Flow Cytometry , HLA-DR Antigens/immunology , HLA-DR Antigens/metabolism , Humans , Immunohistochemistry , Lymphocyte Activation , Lymphocyte Culture Test, Mixed , Microscopy, Confocal
7.
J Thromb Haemost ; 1(5): 1019-23, 2003 May.
Article in English | MEDLINE | ID: mdl-12871371

ABSTRACT

On the basis of plasma interleukin levels it was suggested that there is an inflammatory component to the risk of venous thrombotic disease. Other evidence shows that elevated levels of coagulation factor (F)VIII, FIX, FX and FXI are risk indicators for venous thrombosis, but the reasons for elevation remain unclear. We tested the hypothesis that the elevated levels could reflect an inflammatory reaction by measuring coagulation factor levels during experimental human endotoxemia. Male volunteers received endotoxin (4 ng kg-1), and blood samples were obtained before and at multiple time points after the challenge. Plasma was used for a panel of coagulation tests. Antigen levels of FVIII, von Willebrand factor (VWF), FIX, and FX were increased after endotoxin administration, reaching peak levels between 2 and 5 h. Within 24 h levels normalized, except for FVIII and VWF levels that remained at > 200%. Fibrinogen levels, and to a lesser extent FXI levels, also responded with an increase, but slower. These levels did not return to normal during the observation period. FVII levels were strongly depressed. FVIII, FIX and FX reacted immediately and strongly to endotoxin administration. The time pattern of this response is different from the slower so-called acute phase response, which appeared to be followed by FXI and fibrinogen. These increased levels of coagulation factors during an inflammatory state provide new ways of explaining why elevated levels of FVIII, FIX and FXI behave as risk indicators disease.


Subject(s)
Blood Coagulation Factors/metabolism , Endotoxemia/blood , Lipopolysaccharides/pharmacology , Adult , Blood Coagulation Factors/drug effects , Blood Coagulation Tests , Humans , Inflammation/blood , Inflammation/chemically induced , Kinetics , Lipopolysaccharides/administration & dosage , Male
8.
Article in English | MEDLINE | ID: mdl-12062209

ABSTRACT

The immunomodulatory effect of hyperbaric oxygen, involving altered cytokine release by macrophages, is well described. Importantly, however, it is not known what the relative contribution is of the hyperbaric environment of the cells vs. increased oxygen tension on these hyperbaric oxygen-dependent effects. We compared, therefore, cytokine release by murine macrophages under hyperbaric oxygen, hyperpressure of normal air and normobaric conditions. We observed that hyperbaric oxygen enhanced cytokine release of both unstimulated as well as lipopolysaccharide (LPS)-challenged macrophages. Hyperpressure of normal air, however, enhanced LPS-induced cytokine production but did not elicit cytokine release in unstimulated macrophages. To further investigate the molecular details underlying the effects of hyperbaric oxygen, we investigated the effect of the p42/p44 mitogen-activated protein (MAP) kinase inhibitor PD98059 and the p38 MAP kinase inhibitor SB203580. Neither inhibitor, however, had a significant effect on the modulatory effects of hyperbaric oxygen on cytokine release. We concluded that the immunomodulatory effect of hyperbaric oxygen contains a component for which hyperpressure is sufficient and a component that apart from hyperpressure also requires hyperoxygenation.


Subject(s)
Hyperbaric Oxygenation , Macrophages/drug effects , Macrophages/immunology , Oxygen/pharmacology , Animals , Cells, Cultured , Dimethyl Sulfoxide/pharmacology , Enzyme Inhibitors/pharmacology , Flavonoids/pharmacology , Imidazoles/pharmacology , Lipopolysaccharides/pharmacology , Macrophages/enzymology , Macrophages/metabolism , Mice , Mitogen-Activated Protein Kinase 1/antagonists & inhibitors , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinases/metabolism , Pyridines/pharmacology , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factor-alpha/metabolism , p38 Mitogen-Activated Protein Kinases
9.
Gut ; 50(4): 507-12, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11889071

ABSTRACT

BACKGROUND: Crohn's disease is characterised by a chronic relapsing inflammation of the bowel in which proinflammatory cytokines play an important perpetuating role. Mitogen activated protein kinase p38 (p38 MAPK) has been established as a major regulator of the inflammatory response, especially with regard to production of proinflammatory cytokines, but its role in inflammatory bowel disease is unexplored. In this paper we describe the effects of a specific p38 MAPK inhibitor, SB 203580, in trinitrobenzene sulphonic acid (TNBS) induced colitis in mice. RESULTS: SB 203580 had a dichotomal effect in TNBS mice. Weight loss of TNBS mice treated with SB 203580 was significantly worse and colon weight on sacrifice was significantly increased in MAPK inhibitor treated TNBS mice (229.2 mg and 289.1 mg, respectively). However, the total number of cells in the caudal lymph node decreased to 188.8 x 10(4) cells in SB 203580 treated TNBS mice compared with 334 x 10(4) cells in vehicle treated mice. CD3/CD28 double stimulated caudal lymph node cells of SB 203580 treated mice showed decreased interferon gamma production but increased tumour necrosis factor alpha production. The concentration of interleukin 12p70 in colon homogenates was significantly decreased in SB 203580 treated mice whereas concentrations of interleukin 12p40, tumour necrosis factor alpha, and interleukin 10 were similar in vehicle and SB 203580 treated TNBS mice. CONCLUSION: Our results reveal a dichotomy in p38 MAPK action during experimental colitis.


Subject(s)
Colitis/enzymology , Enzyme Inhibitors/pharmacology , Imidazoles/pharmacology , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Pyridines/pharmacology , Animals , Blotting, Western , Colitis/chemically induced , Enzyme Activation , Enzyme-Linked Immunosorbent Assay , Interferon-gamma/metabolism , Mice , Mice, Inbred BALB C , Mitogen-Activated Protein Kinases/metabolism , T-Lymphocytes/metabolism , Trinitrobenzenesulfonic Acid , Tumor Necrosis Factor-alpha/metabolism , Wasting Syndrome/etiology , Weight Loss , p38 Mitogen-Activated Protein Kinases
10.
J Immunol ; 166(1): 582-7, 2001 Jan 01.
Article in English | MEDLINE | ID: mdl-11123340

ABSTRACT

p38 mitogen-activated protein kinase (MAPK) has been suggested as a mediator of cytokine release and is currently being targeted for anti-inflammatory therapy. However, experimental data are contradictory and lack sufficient affirmation in vivo. We tested the effect of p38 MAPK inhibition in several cell types and in different murine models of infectious disease. We observed that most cell types react to p38 MAPK inhibition with diminished cytokine release, but that this treatment induced increased cytokine release in macrophages. Furthermore, we observed increased cytokine production in mouse models of pneumococcal pneumonia and tuberculosis accompanied by severely reduced bacterial clearance. This apparent inefficacy of p38 MAPK inhibition in reducing cytokine release in infectious disease, as well as its immune-compromising action, suggest that targeting p38 MAPK may not be a suitable anti-cytokine strategy in patients with such disease or at risk for infection.


Subject(s)
Cytokines/metabolism , Endotoxemia/immunology , Macrophages, Peritoneal/metabolism , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Pneumonia, Pneumococcal/immunology , Tuberculosis/immunology , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Cells, Cultured , Cytokines/biosynthesis , Disease Models, Animal , Endotoxemia/enzymology , Enzyme Inhibitors/administration & dosage , Female , Humans , Imidazoles/administration & dosage , Injections, Intraperitoneal , Macrophages, Peritoneal/immunology , Mice , Mice, Inbred BALB C , Mitogen-Activated Protein Kinases/physiology , Pneumonia, Pneumococcal/enzymology , Pyridines/administration & dosage , Tuberculosis/enzymology , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/metabolism , Up-Regulation/drug effects , Up-Regulation/immunology , p38 Mitogen-Activated Protein Kinases
11.
Mol Med ; 7(11): 755-60, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11788789

ABSTRACT

BACKGROUND: All three major members of the MAPK family (i.e., p38 MAPK, p42/p44 MAPK, and c-Jun N terminal kinase (JNK)) have been shown to control cellular responses to inflammation in vitro. Therefore these kinases have been designated suitable targets for anti-inflammatory therapy. However, the extent to which these kinases are actually activated during inflammation in humans in vivo has not been investigated. We employed experimental human endotoxemia, a model of systemic inflammation, to address this question. MATERIALS AND METHODS: Male volunteers were intravenously infused with 4 ng/kg bw lipopolysaccharide (LPS). Directly before LPS infusion and up to 24 h thereafter, activation of p38 MAPK, p42/p44 MAPK and JNK was assessed in peripheral blood, using Western blot and in vitro kinase assays. RESULTS: We observed that LPS induced a strong but transient phosphorylation and activation of p38 MAPK and p42/p44 MAPK, maximal activity being reached after 1 hr of LPS infusion. Strikingly, no JNK phosphorylation or activation was detected under these circumstances. CONCLUSIONS: These results suggest that both inhibitors of p38 MAPK and p42/p44 MAPK but not JNK are potentially useful for anti-inflammatory therapy.


Subject(s)
Endotoxemia/blood , Mitogen-Activated Protein Kinase 1/blood , Mitogen-Activated Protein Kinases/blood , Signal Transduction , Adult , Blotting, Western , Enzyme Activation , Humans , JNK Mitogen-Activated Protein Kinases , Leukocytes/metabolism , Lipopolysaccharides/administration & dosage , Mitogen-Activated Protein Kinase 3 , Phosphorylation , p38 Mitogen-Activated Protein Kinases
12.
Arch Immunol Ther Exp (Warsz) ; 48(6): 539-45, 2000.
Article in English | MEDLINE | ID: mdl-11197609

ABSTRACT

Idiopathic pulmonary fibrosis (IPF) is a devastating disease with an almost universally terminal outcome. In recent years much insight has been gained into the pathogenesis of IPF from both a bleomycin mice-model as well as ex vivo human tissue studies. Alveolar damage and inflammation of unknown etiology, eventually leading to interstitial fibrosis, characterize IPF. Apoptosis has emerged as an important factor in the pathogenesis of IPF. This review will outline the current understanding of the immunological and molecular mechanisms underlying IPF and discuss new therapeutic strategies.


Subject(s)
Pulmonary Fibrosis/etiology , Pulmonary Fibrosis/therapy , Animals , Apoptosis , Chemokines/physiology , Cytokines/physiology , Fibrinolysis , Herpesvirus 4, Human/pathogenicity , Humans , Inflammation/etiology , Mice , Pulmonary Fibrosis/pathology , T-Lymphocytes/physiology , fas Receptor/physiology
13.
Microsc Res Tech ; 46(6): 418-33, 1999 Sep 15.
Article in English | MEDLINE | ID: mdl-10504218

ABSTRACT

The fundamental importance of calcium signaling in the control of cellular physiology is widely recognized. A dramatic illustration of this is the fact that a Medline search for review articles containing the word "calcium" in the title reveals 4,629 hits, whereas the whole body of calcium signaling literature (approximately 2 x 10(6) pages) is more than enough to fill a decent-sized library. Most of this literature deals with calcium signaling in excitable cells types (mainly neurons and muscle cells), but non-excitable cell types are capable of calcium signaling as well. Although calcium fluxes in the latter cell types have attracted much less interest, the literature involved is still vast. Nevertheless, in this review article we hope to contribute some valuable insights to the field. First we shall discuss the experimental techniques available to the researcher interested in calcium signaling in non-excitable cell types with special attention to patch clamp electrophysiology. Subsequently, we shall review some of the results obtained with these techniques by focussing on the calcium-regulating mechanisms in non-excitable cells and discussing the importance of these mechanisms for physiology.


Subject(s)
Calcium Signaling , Animals , Calcium/analysis , Calcium/metabolism , Cell Nucleus/metabolism , Endoplasmic Reticulum/metabolism , GTP-Binding Proteins/physiology , Humans , Mitochondria/metabolism , Receptors, Cell Surface/physiology
14.
Exp Hematol ; 27(3): 553-60, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10089919

ABSTRACT

Paclitaxel is a promising drug for the treatment of breast and ovarian cancer. It also may play a role in mobilization of peripheral blood stem cells (PBSC), as an alternative to cyclophosphamide (Cy). We investigated the PBSC-mobilizing potential of paclitaxel compared to Cy in a murine model. C57B1/6 mice were primed with intraperitoneal injections of Cy (200 mg/kg) or paclitaxel (60 mg/kg) and were sacrificed 4, 6, 8, or 10 days later. Spleens were harvested and processed to obtain low-density mononuclear cells that were used as PBSC. The number of hematopoietic progenitors (CFU-C) on day 4 was significantly higher in the paclitaxel group when compared to mice receiving Cy (72.0 +/- 1.8 vs 9.8 +/- 2.8, p < 0.001). By day 6, CFU-C became significantly higher in the Cy-treated group compared to the paclitaxel-treated group (195.6 +/- 31.9 vs 95.8 +/- 20.7, p < 0.05) and this trend was maintained. However, the total number of CFU-C recovered per spleen was greater in the paclitaxel-treated group (1.27 x 10(5) +/- 0.53 x 10(5) vs 1.06 x 10(5) +/- 0.36 x 10(5), NS). In contrast to paclitaxel, mobilization with Cy was associated with marked perturbation in the proportion of lymphoid cell subsets in the PBSC population along with functional impairment of lymphocytes. After 24 hours of in vitro IL-2 activation, the cytotoxic effector cell function of the Cy-mobilized PBSC population was lower than that of paclitaxel-mobilized cells when tested against three tumor cell lines (B16, melanoma; C1498, AML; and Yak-1, lymphoma). These results indicate that paclitaxel is an efficient mobilizer of PBSC, leading to early (day 4 to 6) mobilization of PBSC when compared to Cy (day 6 to 8). In addition, paclitaxel was associated with less perturbation of phenotypic and functional characteristics of cells contained within the mobilized PBSC population.


Subject(s)
Cyclophosphamide/pharmacology , Hematopoietic Stem Cell Mobilization/methods , Paclitaxel/pharmacology , Animals , Concanavalin A/pharmacology , Cytotoxicity, Immunologic , Drug Evaluation, Preclinical , Female , Interleukin-2/pharmacology , Lipopolysaccharides/pharmacology , Lymphocyte Activation , Mice , Mice, Inbred C57BL , Spleen/cytology , Tumor Cells, Cultured
15.
Scand J Gastroenterol ; 31(12): 1176-81, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8976009

ABSTRACT

BACKGROUND: Diarrhoea is an important problem in human immunodeficiency virus (HIV)-infected patients. Intestinal pathologic conditions may arise from changes in local immunocyte populations. The aims of our study were to establish the histologic features of the duodenal mucosa of HIV-infected patients and to determine a) the phenotype of small-intestinal-intraepithelial (IELs) and lamina propria (LPLs)-lymphocytes; b) their degree of activation and differentiation within the lamina propria; and c) their relation to the presence of diarrhoea. METHODS: Distal duodenal biopsy specimens were obtained prospectively from 29 HIV-infected patients-11 patients with diarrhoea (group 1) and 18 patients without diarrhoea (group 2)- and from 42 patients who had neither any risk factor for HIV nor diarrhoea (group 3). Histopathologic and immunohistochemical studies were combined with flow cytometric analysis, after separation of the mucosal intraepithelial compartment from the lamina propria. RESULTS: The median number of IELs and the percentage of gamma delta IELs were both unchanged in HIV-infected patients as compared with controls. In HIV-infected patients LP CD4 cells were decreased, and LP CD8 cells increased. No significant difference was found in the expression of CD25 or CD27 within the LP CD8 populations of HIV-infected patients in groups 1 and 2. CONCLUSIONS: These findings suggest that the occurrence of diarrhoea in HIV-infected patients is unrelated to IEL and LPL phenotype.


Subject(s)
Diarrhea/immunology , HIV Infections/immunology , Intestinal Mucosa/immunology , Adult , Aged , Biopsy , CD4 Lymphocyte Count , CD4-CD8 Ratio , CD4-Positive T-Lymphocytes , Chi-Square Distribution , Diarrhea/etiology , Diarrhea/pathology , Duodenum , Female , HIV Infections/complications , HIV Infections/pathology , Humans , Immunohistochemistry , Intestinal Mucosa/pathology , Male , Middle Aged , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...